What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Key Points
Quantedge Capital exited 89,600 shares of Supernus Pharmaceuticals in the first quarter, with an estimated trade size of $4.56 million based on quarterly average prices.
The transaction represented 2.5% of Quantedge’s 13F reportable assets under management.
The position was previously 2.1% of the fund’s AUM as of the prior quarter.
- 10 stocks we like better than Supernus Pharmaceuticals ›
On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it sold out its entire stake in Supernus Pharmaceuticals (NASDAQ:SUPN) during the first quarter, with an estimated transaction value of $4.56 million based on quarterly average pricing.
What happened
According to an SEC filing dated May 12, 2026, Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals during the first quarter. The estimated value of the trade was $4.56 million, calculated using the average closing price for the period. As a result, the fund’s position in Supernus Pharmaceuticals fell to zero, with a net position value decrease of $4.45 million for the quarter.
What else to know
- Top holdings after the filing:
- NYSE:PVH: $32.40 million (17.7% of AUM)
- NYSE:HLF: $28.29 million (15.5% of AUM)
- NYSE:BWA: $19.09 million (10.4% of AUM)
- NASDAQ:TXG: $8.84 million (4.8% of AUM)
- NYSE:ADNT: $7.91 million (4.3% of AUM)
- As of May 11, 2026, Supernus Pharmaceuticals shares were priced at $49.37, up 56% over the past year and well outperforming the S&P 500’s roughly 26% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-05-11) | $49.37 |
| Market capitalization | $2.87 billion |
| Revenue (TTM) | $719 million |
| Net income (TTM) | ($38.6 million) |
Company snapshot
- Supernus Pharmaceuticals develops and commercializes specialty pharmaceuticals for central nervous system (CNS) disorders, with a portfolio including Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
- The company generates revenue primarily through the sale of branded prescription drugs marketed to healthcare providers, wholesalers, specialty pharmacies, and distributors across the United States.
- Its main customers are healthcare professionals treating epilepsy, migraine, ADHD, Parkinson's disease, and other CNS conditions, as well as specialty pharmacies and pharmaceutical distributors.
Supernus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on innovative therapies for central nervous system diseases. The company leverages a diverse portfolio of approved products and late-stage pipeline candidates to address unmet medical needs in neurology and psychiatry. With a broad commercial reach and ongoing investment in research and development, Supernus aims to maintain its competitive position in the specialty pharmaceutical market.
What this transaction means for investors
Quantedge exited Supernus entirely, but the company’s latest results (from last week) suggest the broader turnaround story is still gaining traction. That might suggest this move was more about locking in gains than necessarily a shift in conviction.
Supernus just reported first-quarter revenue growth of 39% to $207.7 million, driven by rapid expansion across its newer growth products. Combined revenue from key products, including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO jumped 56% to $149.1 million. The company also reiterated full-year guidance calling for as much as $870 million in revenue.
Importantly, the business is becoming less dependent on older epilepsy drugs that are steadily declining because of generic competition. Qelbree sales rose 20% to $77.9 million, while collaboration revenue tied to Biogen-partnered postpartum depression drug ZURZUVAE added another $27.6 million.
Whether the company can continue on that path will be important, and of note, it also finished the quarter with roughly $384 million in cash and marketable securities, giving it flexibility to continue investing in pipeline development and commercialization efforts.
Should you buy stock in Supernus Pharmaceuticals right now?
Before you buy stock in Supernus Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Supernus Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $460,826!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,345,285!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 12, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 10x Genomics. The Motley Fool recommends BorgWarner. The Motley Fool has a disclosure policy.
Recommended Articles
